A carregar...
Bilateral above knee amputations after prolonged exposure to sorafenib and trebananib
Sorafenib is an oral tyrosine kinase inhibitor (TKI) that acts on many targets including RAF kinases, vascular endothelial growth factor (VEGF) 1, 2, 3, platelet derived growth factor and c-kit receptor and is currently FDA approved for unresectable hepatocellular carcinoma (HCC). Trebananib (AMG 38...
Na minha lista:
| Publicado no: | J Gastrointest Oncol |
|---|---|
| Main Authors: | , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Pioneer Bioscience Publishing Company
2014
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4226824/ https://ncbi.nlm.nih.gov/pubmed/25436132 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3978/j.issn.2078-6891.2014.049 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|